Zenas BioPharma Inc

For the period ended Dec 31, 2024. Filed Mar 11, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 11, 2025

ZBIO$28.58+0.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)


· · ·
· · · Years Ended December 31,
	2024	2023
Revenue:
License and collaboration revenue	$5,000	$50,000
Total revenue	5,000	50,000
Operating expenses:
Research and development (includes $3,524 and $3,041 from related parties, respectively)	139,139	60,033
General and administrative (includes $0 and $8 from related parties, respectively)	29,749	17,114
Acquired in-process research and development	—	10,000
Total operating expenses	168,888	87,147
Loss from operations	(163,888)	(37,147)
Other income, net:
Fair value adjustments to convertible notes	(846)	(300)
Other income, net	8,175	624
Total other income (expense), net	7,329	324
Loss before income taxes	(156,559)	(36,823)
Income tax provision	(429)	(301)
Net loss to common stockholders	$(156,988)	$(37,124)
Net loss per share attributable to common stockholders - basic and diluted	$(11.89)	$(24.25)
Weighted-average common stock outstanding - basic and diluted	13,198,960	1,531,178
Comprehensive loss:
Net loss to common stockholders	$(156,988)	$(37,124)
Other comprehensive income:
Unrealized gain on marketable securities, net tax	31	—
Foreign currency translation adjustment	126	78
Comprehensive loss	$(156,831)	$(37,046)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.